Company Description
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer.
Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and oropharyngeal squamous cell carcinoma.
The company is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3.
The company was founded in 2007 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 2007 |
| IPO Date | Dec 16, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 41 |
| CEO | Jay Short |
Contact Details
Address: 11085 Torreyana Road San Diego, California 92121 United States | |
| Phone | 858 558 0708 |
| Website | bioatla.com |
Stock Details
| Ticker Symbol | BCAB |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0001826892 |
| CUSIP Number | 09077B203 |
| ISIN Number | US09077B2034 |
| Employer ID | 85-1922320 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jay M. Short Ph.D. | Co-Founder, Chief Executive Officer and Chairman |
| Dr. Eric L. Sievers M.D. | Chief Medical Officer |
| Susie Melody | Senior Vice President of Human Resources |
| Dr. Cathy Chang Ph.D. | Senior Vice President of Research and Development |
| Dr. Gerhard Frey Ph.D. | Senior Vice President of Technology Development |
| Monica Sullivan | Senior Vice President of Intellectual Property and Contracts |
| Sheri Lydick | Chief Commercial Officer |
| Lisa M. Pelton | Accounting Manager |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 3, 2026 | ARS | Filing |
| Jun 3, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jun 3, 2026 | DEF 14A | Other definitive proxy statements |
| May 15, 2026 | 10-Q | Quarterly Report |
| Apr 29, 2026 | 10-K/A | [Amend] Annual report |
| Apr 2, 2026 | 8-K | Current Report |
| Mar 31, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 31, 2026 | 10-K | Annual Report |
| Mar 31, 2026 | 8-K | Current Report |
| Mar 23, 2026 | 8-K | Current Report |